Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 61 of the 66 references it cites were found in a registry or an index.
Abstract
oth the prevalence and incidence of type 2 diabetes are increasing worldwide in conjunction with increased Westernization of the population's lifestyle.Type 2 diabetes is still a leading cause of cardiovascular disease (CVD), amputation, renal failure, and blindness.The risk for microvascular complications is related to overall glycemic burden over time as measured by A1C (1,2).The UK Prospective Diabetes Study (UKPDS) 10-year follow-up demonstrated a possible effect on CVD as well (3).A meta-analysis of cardiovascular outcome in patients with long disease duration including Action to Control Cardiovascular Risk in Diabetes (ACCORD), Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE), and Veterans Affairs Diabetes Trial (VADT) suggested that in these populations the reduction of ~1% in A1C is associated with a 15% relative reduction in nonfatal myocardial infarction (4).Most antihyperglycemic drugs besides insulin reduce A1C values to similar levels (5) but differ in their safety elements and pathophysiological effect.Thus, there is a need for recommending a drug therapy preference.While the positive effects on prevention of microvascular complications were demonstrated with the various antihyperglycemic drugs (1,2,6,7), several questions are left open regarding this therapy in newly diagnosed type 2 diabetes:
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“There are a range of effective treatments that reduce hyperglycaemia in T2D patients, which mediate their effects by improving insulin secretion or decreasing peripheral tissue insulin resistance.8”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [8]
In the citing paper
“Metformin decreases hepatic glycogenolysis, decreases peripheral tissue insulin resistance, increases GLP-1 postprandial secretion (which augments insulin secretion), and delays digestion.8”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [8]
In the citing paper
“Common side effects of insulin secretagogues include weight gain and hypoglycaemia, and these drugs are only usually effective in the short term.8”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [8]
In the citing paper
“Additionally, it was implicated that GLP-1 analogue therapy increased the risk of acute pancreatitis, but subsequent studies using larger cohorts did not confirm this finding.8,267”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“The UK Prospective Diabetes Study (UKPDS) 10-year follow-up demonstrated a possible effect on CVD as well (3).”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 2×
“Our past experience with antihyperglycemic drugs is that recommendations to stepwise increase these drugs whenever A1C is above target might fail to prevent disease progression (1,6), necessitating intensive insulin therapy over time.”
BackgroundGupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Ray, K. K., Seshasai, S. R. K., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D., Erqou, S., & Sattar, N. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60697-8 · Cited by 1,383
Booth, G., & Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.010 · Cited by 1,220
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · cited 1×
“In physiological circumstances, GLP-1 and GIP have an extremely short halflife, as they are almost immediately inactivated by the DPP-4 enzyme (47).”
BackgroundPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 2×
“(30) showed a 6- to 10-fold increase in pancreatitis in patients treated with the DPP-4 inhibitor sitagliptin or with exenatide in comparison with patients treated with the control drugs rosiglitazone, nateglinide, reparglinide, or glipizide (43 events).”
BackgroundResultRodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942
Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study
Currie, C. J., Peters, J. R., Tynan, A., Evans, M., Heine, R. J., Bracco, O. L., Zagar, T., & Poole, C. D. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61969-3 · Cited by 874
Cheng, A. Y. Y. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.009 · Cited by 728
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 1×
“It has also been observed in preclinical studies that incidence of thyroid C-cell tumors was increased in rodents treated with GLP-1 analogs (31).”
BackgroundRisk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
[Management of hyperglycaemia in type 2 diabetes: a patient-centered approach].
Scheen, A. J., & Mathieu, C. (2012) · PubMed · Cited by 581
Stoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 2×
“The elevation of circulating incretin concentrations is a desired effect in patients with type 2 diabetes, as it restores the incretin effect on b-cells that has been shown to be reduced in type 2 diabetes (48).”
BackgroundSingh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467 · cited 1×
“The issue of pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis as well as the increased risk for cancer (32,33,53,54), has not yet been resolved.”
BackgroundButler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Calvert, J. W., Gundewar, S., Jha, S., Greer, J. J. M., Bestermann, W. H., Tian, R., & Lefer, D. J. (2008) · Diabetes · doi:10.2337/db07-1098 · Cited by 422
Schramm, T. K., Gislason, G. H., Vaag, A., Rasmussen, J. N., Folke, F., Hansen, M. L., Fosbøl, E. L., Køber, L., Norgaard, M. L., Madsen, M., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr077 · Cited by 418
Clinical Inertia in Response to Inadequate Glycemic Control
Shah, B. R., Hux, J. E., Laupacis, A., Zinman, B., & van Walraven, C. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.600 · Cited by 388
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Garg, R., Chen, W., & Pendergrass, M. (2010) · Diabetes Care · doi:10.2337/dc10-0482 · Cited by 322
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul-Ghani, M. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 314
Fuhlendorff, J., Rorsman, P., Kofod, H., Brand, C. L., Rolin, B., MacKay, P., Shymko, R., & Carr, R. D. (1998) · Diabetes · doi:10.2337/diabetes.47.3.345 · Cited by 310
The natural history of hereditary pancreatitis: a national series
Rebours, V, Boutron-Ruault, M.-C., Schnee, M., Férec, C., Le Maréchal, C., Hentic, O., Maire, F., Hammel, P., Ruszniewski, P., & Lévy, P. (2009) · Gut · doi:10.1136/gut.2008.149179 · Cited by 306
Neumann, A., Weill, A., Ricordeau, P., Fagot, J. P., Alla, F., & Allemand, H. (2012) · Diabetologia · doi:10.1007/s00125-012-2538-9 · Cited by 284
Azoulay, L., Yin, H., Filion, K. B., Assayag, J., Majdan, A., Pollak, M. N., & Suissa, S. (2012) · BMJ · doi:10.1136/bmj.e3645 · Cited by 270
Raz, I., Eldor, R., Cernea, S., & Shafrir, E. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.493 · Cited by 194
Self-citationChaiteerakij, R., Yang, J. D., Harmsen, W. S., Slettedahl, S. W., Mettler, T. A., Fredericksen, Z. S., Kim, R. W., Gores, G. J., Roberts, R. O., Olson, J. E., et al. (2013) · Hepatology · doi:10.1002/hep.26092 · Cited by 149
Exenatide (Exendin-4)–Induced Pancreatitis
Denker, P. S., & Dimarco, P. E. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-2043 · Cited by 140
Delahanty, L. M., Peyrot, M., Shrader, P. J., Williamson, D. A., Meigs, J. B., Nathan, D. M., & for the DPP Research Group (2013) · Diabetes Care · doi:10.2337/dc12-0733 · Cited by 130
Johnson, M., Jones, R., Freeman, C., Woods, H. B., Gillett, M., Goyder, E., & Payne, N. (2013) · Diabetic Medicine · doi:10.1111/dme.12018 · Cited by 123
The effect of metformin and thiazolidinedione use on lung cancer in diabetics
Mazzone, P. J., Rai, H., Beukemann, M., Xu, M., Jain, A., & Sasidhar, M. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-410 · Cited by 112
Bennett, W. L., Odelola, O. A., Wilson, L. M., Bolen, S. D., Selvaraj, S. A., Robinson, K. A., Bass, E. B., & Puhan, M. A. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-1-201201030-00005 · Cited by 101
Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
Schernthaner, G., Currie, C. J., & Schernthaner, G.-H. (2013) · Diabetes Care · doi:10.2337/dcs13-2031 · Cited by 100
Idris, I., Warren, G., & Donnelly, R. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.1938 · Cited by 88
Ban, K., Hui, S., Drucker, D. J., & Husain, M. (2009) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2009.04.001 · Cited by 88
PPAR- γ Agonist in Treatment of Diabetes: Cardiovascular Safety Considerations
Abbas, A., Blandon, J., Rude, J., Elfar, A., & Mukherjee, D. (2012) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/187152512800388948 · Cited by 76
Incretin agents in type 2 diabetes.
Ross, S. A., & Ékoé, J.-M. (2010) · PubMed · Cited by 59
Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells
Krizhanovskii, C., Patrone, C., Holst, J. J., Zhang, Q., & Sjöholm, Å. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0637-5 · Cited by 55
Individualizing Targets and Tactics for High-Risk Patients With Type 2 Diabetes
Riddle, M. C., & Karl, D. M. (2012) · Diabetes Care · doi:10.2337/dc12-0650 · Cited by 51
Remillard, C., MacConell, Li, Pencek, Maggs, & Porter (2013) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s35801 · Cited by 50
Bone Loss and Fracture Risk Associated with Thiazolidinedione Therapy
Riche, D. M., & King, S. T. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.7.716 · Cited by 33
Prevention of diabetes: a strategic approach for individual patients
Shin, J., Lee, J., Kim, H., Choi, Y., Cho, J., & Yoon, K. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2357 · Cited by 28
Caputo, S., Andersen, H., Kaiser, M., Karnieli, E., Meneghini, L., & Svendsen, A. L. (2013) · Endocrine Practice · doi:10.4158/ep12269.or · Cited by 17
Raz, I., & Eldor, R. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2265 · Cited by 15
Self-citationPancreatitis Associated With Incretin-Based Therapies
Iyer, S. N., Tanenberg, R. J., Mendez, C. E., West, R. L., & Drake, A. J. (2013) · Diabetes Care · doi:10.2337/dc12-1987 · Cited by 12
Caputo, S., Andersen, H., Kaiser, M., Karnieli, E., Meneghini, L., Svendsen, A. L., & Gemelli, P. (2012) · Cited by 4
Incretin-based therapies: A focus on safety concerns and emerging uses
Prasad‐Reddy, L., & Williams, K. L. (2012) · Cited by 1
Cited by
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes
Tseng, C. (2018) · Liver International · doi:10.1111/liv.13872 · Cited by 132
Lin, H.-T., Tsou, Y.-C., Chen, Y.-T., Lu, W.-J., & Hwang, P.-A. (2017) · Marine Drugs · doi:10.3390/md15040113 · Cited by 114
Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
Cinti, F., Moffa, S., Impronta, F., Cefalo, C. M. A., Sun, V. A., Sorice, G. P., Mezza, T., & Giaccari, A. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s114932 · Cited by 91
Post-transplantation diabetes—state of the art
Sharif, A., & Cohney, S. J. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00387-3 · Cited by 99
Metadata
- Authors
- Raz, I.
- Affiliations
- Hadassah Medical Center (IL)
- Corresponding author
- Raz, Itamar
- ORCID
- Raz, Itamar
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-07-17
- Volume
- 36
- Issue
- Supplement_2
- Pages
- S139-S144
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3920774
- OpenAlex
- W2087910657
- Cited by
- 71
- References
- 66
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 7 · 2023: 2 · 2022: 3 · 2021: 7 · 2020: 3 · 2019: 5 · 2018: 5 · 2017: 7 · 2016: 7 · 2015: 6 · 2014: 11 · 2013: 1
- FWCI
- 6.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, newly diagnosed diabetes, antidiabetic drugs, glycemic control, HbA1c, cardiovascular risk, microvascular complications, drug therapy selection, treatment guidelines
- MeSH terms
- Algorithms, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Humans, Hypoglycemic Agents, Practice Guidelines as Topic, Guideline Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.